Yarrow Bioscience, Inc.
YARW Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$19.27
KIRA · Stoqly’s AI analyst, in plain words
- Yarrow Bioscience, Inc. had $0.6M of revenue in fiscal 2025, up 13.8% on the year before. Over five years, revenue changed −51.4% a year on average.
- Its operating margin was −5,219.1%, up 3,490.9 pts: of every 100 in sales, about −5,219 is left after running the business.
- Yarrow Bioscience, Inc. lost $26.5M in fiscal 2025.
- Free cash flow was −$33.1M in fiscal 2025, −5,811.2% of revenue.
- Yarrow Bioscience, Inc. has $29.0M more cash than debt.
Market cap
$16.5M
P/E
—
Revenue
$0.6M
Net income
−$26.5M
Free cash flow
−$33.1M
Operating margin
−5,219.1%
Yarrow Bioscience, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+13.8%
Yes. Sales grew 13.8% last year.
Does it make a profit?
−4,646.1%
No. It lost money last year.
Does profit turn into cash?
−5,811.2%
No. It spent more cash than it brought in.
How healthy are the accounts?
2 / 8
Weak. It passes 2 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Yarrow Bioscience, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 27, 2026
- Legal name
- Yarrow Bioscience, Inc.
- CIK
- 0001566044
Yarrow Bioscience, Inc. · YARW
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.9M | $0.5M | $0.4M | $0.5M | $0.6M |
| Revenue growth | −95.6% | −48.8% | −11.1% | 18.2% | 13.8% |
| Gross margin | −259.6% | — | — | — | — |
| Operating margin | −4,179.5% | −7,189.7% | −6,900.5% | −8,710.0% | −5,219.1% |
| Net income | −$73.3M | −$23.2M | −$28.5M | −$39.8M | −$26.5M |
| Net margin | −7,876.4% | −4,865.8% | −6,710.4% | −7,950.9% | −4,646.1% |
| Diluted EPS | −$25.64 | −$7.28 | −$2.78 | −$0.93 | −$0.62 |
| Cash | |||||
| Cash from operations | −$56.4M | −$29.2M | −$25.3M | −$34.0M | −$33.1M |
| Capital expenditure | $0.0M | — | $0.0M | $0.1M | $0.0M |
| Free cash flow | −$56.4M | — | −$25.3M | −$34.1M | −$33.1M |
| FCF margin | −6,054.5% | — | −5,976.7% | −6,804.2% | −5,811.2% |
| Share count change | −91.2% | 11.4% | 222.4% | 314.6% | 0.4% |
| Debt and strength | |||||
| Cash and short-term investments | $42.3M | $30.9M | $93.3M | $61.5M | $29.0M |
| Debt incl. finance leases | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | $48.6M | $31.2M | $88.7M | $52.1M | $27.8M |
| Current ratio | 3.4x | 4.1x | 12.7x | 4.3x | 12.5x |
| Interest coverage | −6.9x | — | — | — | — |
| Returns and quality | |||||
| Return on capital | −481.4% | −9,215.3% | — | — | — |
| Return on equity | −170.3% | −58.1% | −47.4% | −56.6% | −66.3% |
| Return on tangible equity | −150.8% | −74.4% | −32.1% | −76.5% | −95.4% |
| Piotroski F-score | 4 | 2 | 3 | 2 | 2 |
| Altman Z'' | −27.8 | −50.5 | −8.7 | −31.5 | −70.3 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Yarrow Bioscience, Inc. · YARW
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $19.27 a share, the company is worth $16.5M.
Source: SEC EDGAR XBRL filings (CIK 0001566044). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.